An association study of 43 SNPs in 16 candidate genes with atorvastatin response
Open Access
- 16 August 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 5 (6), 352-358
- https://doi.org/10.1038/sj.tpj.6500328
Abstract
Variation in individual response to statin therapy has been widely studied for a potential genetic component. Multiple genes have been identified as potential modulators of statin response, but few study findings have replicated. To further examine these associations, 2735 individuals on statin therapy, half on atorvastatin and the other half divided among fluvastatin, lovastatin, pravastatin and simvastatin were genotyped for 43 SNPs in 16 genes that have been implicated in statin response. Associations with low-density lipoprotein cholesterol (LDL-C) lowering, total cholesterol lowering, HDL-C elevation and triglyceride lowering were examined. The only significant associations with LDL-C lowering were found with apoE2 in which carriers of the rare allele who took atorvastatin lowered their LDL-C by 3.5% more than those homozygous for the common allele and with rs2032582 (S893A in ABCB1) in which the two groups of homozygotes differed by 3% in LDL-C lowering. These genetic effects were smaller than those observed with the demographic variables of age and gender. The magnitude of all the differences found is sufficiently small that genetic data from these genes should not influence clinical decisions on statin administration.Keywords
This publication has 27 references indexed in Scilit:
- The −514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatmentAtherosclerosis, 2005
- A promoter polymorphism in cholesterol 7α-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatinAtherosclerosis, 2005
- Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medicationsPreventive Medicine, 2004
- Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease managementAtherosclerosis, 2004
- Lipid-lowering response to statins is affected by CYP3A5 polymorphismPharmacogenetics, 2004
- Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific mannerThe American Journal of Cardiology, 2004
- ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatinJournal of Lipid Research, 2004
- Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapyAtherosclerosis, 2003
- The pharmacogenetics of codeine hypoalgesiaPharmacogenetics, 1995
- Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non‐familial hypercholesterolaemiaJournal of Internal Medicine, 1991